GlassScriptPhysician profile
Brian J Szelc
NPI 1225451750
$5,352.47
in general payments reported to CMS, 2019-2025
25 companies · $2,043 in 2025
The $2,043 reported for 2025 was more than what 92% of Psychiatric/Mental Health (Nurse Practitioner) providers received nationally (typical 2025 total: $257).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $392 · 2022: $357 · 2023: $966 · 2024: $1,595 · 2025: $2,043.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,460 · Education: $144.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,459.66 |
| Education | $143.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $871.93 | 2022-2025 | |
| Teva Pharmaceuticals USA, INC. | $645.37 | 2021-2025 | Austedo Xr, Austedo Xr, Uzedy |
| Janssen Pharmaceuticals, INC | $593.39 | 2021-2025 | Spravato, Invega Sustenna, Invega |
| Otsuka America Pharmaceutical, INC. | $575.50 | 2021-2025 | Rexulti, Abilify Maintena, Abilify Asimtufii |
| Alkermes, INC. | $548.40 | 2021-2025 | Lybalvi, Vivitrol, Vivitrol |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $414.52 | 2021-2025 | Caplyta |
| Tris Pharma INC | $312.93 | 2025 | Dyanavel Xr, Quillichew Er, Quillivant |
| Lundbeck LLC | $278.24 | 2023-2025 | Rexulti, Abilify Maintena |
| Neurocrine Biosciences, INC. | $207.08 | 2022-2025 | Ingrezza |
| Vanda Pharmaceuticals INC. | $204.10 | 2021-2023 | Fanapt, Hetlioz |
| Axsome Therapeutics, INC. | $178.11 | 2022-2025 | Auvelity |
| E.R. Squibb & Sons, L.L.C. | $139.55 | 2025 | Cobenfy |
| Janssen Scientific Affairs, LLC | $79.71 | 2024 | Spravato |
| Takeda Pharmaceuticals U.S.A., INC. | $45.95 | 2023-2025 | Trintellix |
| Collegium Pharmaceutical, INC. | $43.31 | 2025 | Jornay Pm |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Acadia Pharmaceuticals INC | $42.56 | 2023-2024 | Nuplazid |
| Supernus Pharmaceuticals, INC. | $36.62 | 2025 | Qelbree |
| Neuronetics, INC. | $32.34 | 2024 | Neurostar Tms Therapy System |
| Sun Pharmaceutical Industries INC. | $17.18 | 2021 | |
| Noven Therapeutics, LLC | $16.48 | 2021 | |
| Idorsia Pharmaceuticals US INC | $16.23 | 2023 | Quviviq |
| Avanir Pharmaceuticals, INC. | $15.32 | 2022 | |
| Braeburn INC. | $15.08 | 2024 | Brixadi |
| Allergan, INC. | $11.66 | 2021 | |
| Corium, LLC | $10.91 | 2025 | Azstarys |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Brian Szelc listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.